A dual electrophysiologic test for atrial antireentry and ventricular antifibrillatory studies. Effects of bethanidine, procainamide, and WY-48986.
We have developed a dual electrophysiologic test that allows measurement of both antireentry and antifibrillatory activities of potential antiarrhythmics in the same anesthetized dog. The reentry portion of the model was created surgically by a Y-shaped crushing around the tissue between the superior and inferior vena cava and tissue parallel to the AV groove. The pacing-induced tachycardia that results from circus movements around the tricuspid ring is very persistent in duration and regular in cycle length. The antifibrillatory activities were assessed by determination of the ventricular fibrillation threshold (VFT) using train-stimuli method. Control VFT was measured every 15-20 min in duplicate and followed by induction of atrial reentry. A drug was infused to intervene the atrial tachycardia. After the conversion of the arrhythmia (either by drug regimens or pacing), postdrug VFT was measured, again in duplicate. Bethanidine (20 mg/kg), procainamide (30 mg/kg), and WY-48986 (10 mg/kg), a Class III antiarrhythmic, were evaluated in this dual test. Bethanidine and procainamide prolonged the cycle length of atrial reentry to a greater extent than WY-48986. The atrial arrhythmias were consistently terminated by procainamide and WY-48986 whereas bethanidine converted the tachycardias in one of the five dogs studied. All three agents elevated VFT with bethanidine producing higher values than procainamide and WY-48986. In conclusion, the dual electrophysiologic testing system offers both economic and scientific advantages for the study of modes of action of antiarrhythmic agents.
Wu
K M
KM
A. H. Robins Research Laboratory, Richmond, Virginia.
Hunter
T L
TL
Proakis
A G
AG
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001627:Bethanidine / Q000494:pharmacology*; D002304:Cardiac Pacing, Artificial; D004285:Dogs; D004562:Electrocardiography; D004594:Electrophysiology; D005260:Female; D006146:Guanidines / Q000494:pharmacology*; D008297:Male; D009206:Myocardium / Q000473:pathology; D011342:Procainamide / Q000494:pharmacology*; D013424:Sulfanilamides; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000503:physiopathology*; D013617:Tachycardia, Supraventricular / Q000503:physiopathology*; D014693:Ventricular Fibrillation / Q000473:pathology / Q000503:physiopathology*; D000096926:Benzenesulfonamides
D000889:Anti-Arrhythmia Agents; D001627:Bethanidine; D006146:Guanidines; D011342:Procainamide; D013424:Sulfanilamides; C063978:risotilide; D000096926:Benzenesulfonamides